Get started
Author

James P. King

Observed names: J King, J. E. King, J. King, J. W. King, J.W-L. King, Judith King, Judith W. King, Judy King, Judy King, ST, Judy W King, Judy W. King, Judy Wai-Ling King, King, J, King, Judith
Observed institutions: University College Hospital, Royal Marsden NHS Foundation Trust, University College London Hospitals NHS Foundation Trust, Imperial College Healthcare NHS Trust, Royal Free London NHS Foundation Trust, King's College London, Guy's and St Thomas' NHS Foundation Trust, The Royal Free Hospital, Hammersmith Hospital, Whittington Hospital, Barnet Hospital, Whittington Health NHS Trust, North Middlesex University Hospital NHS Trust, Velindre Cancer Centre, North Middlesex Hospital, University College London, Imperial College London
ORCID: 0000-0003-0993-9076
Observed ORCID: 0000-0003-0993-9076
OpenAlex ID: A5087075605
CD3 limits the efficacy of TCR gene therapy in vivo
2011 · Maryam Ahmadi, Judith W. King, et al. · Blood · 120
PDF
A multicentre comparison between Child Pugh and Albumin‐Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma
2016 · Julien Edeline, Jean‐Frédéric Blanc, et al. · Liver International · 96
Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer
2021 · R. Charles Coombes, Holly Tovey, et al. · JAMA Oncology · 54
PDF
Monoclonal T-Cell Receptors: New Reagents for Cancer Therapy
2007 · Hans J Stauss, Michela Cesco-Gaspere, et al. · Molecular Therapy · 53
PDF
WT1-specific T cell receptor gene therapy: Improving TCR function in transduced T cells
2007 · Hans J. Stauss, Sharyn Thomas, et al. · Blood Cells Molecules and Diseases · 52
Fertility Preservation in Women Undergoing Treatment for Breast Cancer in the U.K.: A Questionnaire Study
2012 · Judy W. King, Melanie C. Davies, et al. · The Oncologist · 48
PDF
Hormone replacement therapy and women with premature menopause – A cancer survivorship issue
2011 · Judy King, Catherine Harper Wynne, et al. · European Journal of Cancer · 34
Sorafenib for the Treatment of Advanced Hepatocellular Cancer – a UK Audit
2016 · J. King, D.H. Palmer, et al. · Clinical Oncology · 33
The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience
2020 · Valerie E. Crolley, Husam Marashi, et al. · Breast Cancer Research and Treatment · 32
PDF
Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score
2017 · J. Edeline, J.-F. Blanc, et al. · European Journal of Cancer · 25
Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination
2011 · Constandina Pospori, Shao-An Xue, et al. · Blood · 24
PDF
Advances in tumour immunotherapy
2008 · J. King, J. Waxman, et al. · QJM · 24
Towards saving a million bed days: reducing length of stay through an acute oncology model of care for inpatients diagnosed as having cancer
2011 · J. King, C. Ingham-Clark, et al. · BMJ Quality & Safety · 22
Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience
2019 · Nicolò Matteo Luca Battisti, Belinda Kingston, et al. · Breast Cancer Research and Treatment · 21
IL15 Can Reverse the Unresponsiveness of Wilms' Tumor Antigen-Specific CTL in Patients with Prostate Cancer
2009 · Judy W. King, Sharyn Thomas, et al. · Clinical Cancer Research · 21
A Phase I Study Evaluating the Safety and Persistence of Allorestricted WT1-TCR Gene Modified Autologous T Cells in Patients with High-Risk Myeloid Malignancies Unsuitable for Allogeneic Stem Cell Transplantation
2019 · Emma C Morris, Rita Tendeiro-Rego, et al. · Blood · 18
Axitinib for the treatment of advanced non-small-cell lung cancer
2013 · Judy W King, Siow-Ming Lee · Expert Opinion on Investigational Drugs · 14
UK real-world evidence on pembrolizumab and neoadjuvant chemotherapy for early-stage triple-negative breast cancer
2026 · J. McKeon, E. Daniels, et al. · ESMO Real World Data and Digital Oncology · 8
PDF
A Multicentre Retrospective Study of Fulvestrant Use and Efficacy in Advanced/Metastatic Breast Cancer
2022 · A. Lerner, K. Keshwani, et al. · Clinical Oncology · 8
Real world experience of trastuzumab deruxtecan for the treatment of metastatic breast cancer in the UK.
2024 · Andy Cheng, Suzanne Frank, et al. · Journal of Clinical Oncology · 7
The promiscuous receptor
2009 · Thomas E. Newsom‐Davis, Laura M. Kenny, et al. · British Journal of Urology · 7
PDF
Neo-Adjuvant Chemotherapy
2022 · Judy King, Valerie Crolley, et al. · CRC Press eBooks · 4
231P Trastuzumab deruxtecan for the treatment of metastatic breast cancer in the UK: Real-world data
2023 · A.K. Cheng, S. Frank, et al. · ESMO Open · 3
PDF
PROCURE European consensus on breast cancer multigene signatures in early breast cancer management
2023 · Giuseppe Curigliano, Fatima Cardoso, et al. · npj Breast Cancer · 3
PDF
408TiP INAVO123: Phase III study of first-line (1L) inavolisib/placebo + a CDK4/6 inhibitor + letrozole (INAVO/PBO + CDK4/6i + LET) in participants (pts) with PIK3CA-mutated (mut), hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-sensitive advanced breast cancer (aBC)
2025 · J. Cortés, R.K. Basho, et al. · ESMO Open · 2
PDF
Works count: 74
Citation count: 748
H-index: 16
I10-index: 17
Year
Topic
Type